Healthy Longevity ScienceExplore the questions behind healthy longevity. Understand the evidence, its possibilities and its limits.
70 articles
Measuring agingHorvath’s clock, PhenoAge, GrimAge and DunedinPACE do not measure the same thing. Some produce an age in years; another estimates the pace of aging. Knowing the name, sample and purpose makes a report easier to read—and easier to put alongside ordinary medical tests.
NAD & cellular energyMuscle insulin sensitivity, blood metabolites and heart-pumping function appear in NAD research. These are different results. A closer look at three human studies makes the practical comparison between a capsule and an infusion easier to understand.
Assessment & preventive careHbA1c, a cholesterol panel, a blood-pressure monitor, a DXA scan or an exercise bike with a breathing mask: these can all have a place in medical care. Their value depends on why they are used and what follows the result. Here is how that differs from general wellness support.
Blood and plasma therapiesA donor centre collects plasma for other people. A hospital may exchange a patient’s plasma to remove harmful antibodies, as in some cases of myasthenia gravis or immune TTP. Following the fluid, the replacement and the treatment goal makes the difference concrete.
Measuring agingDifferent parts of the body can show different patterns of aging. Blood-protein models connect some of those patterns with future health; one study included 44,498 people. An “older heart” result is a model estimate, rather than a direct measurement of damage. Its value becomes clearer when you know how the number was produced and what it adds to a care decision.
Personalized preventionA long report can leave you knowing more about your body but less sure where to start. The next consultation should turn those findings into a manageable plan: what needs attention, what needs checking, what you can work on and when to review it. Clear priorities and a shared understanding make the results easier to use in everyday life.
Assessment & preventive careYou may know your cholesterol, blood pressure and weight yet still wonder what to do next. A longevity assessment can bring those pieces together, explore selected questions about strength and fitness, and turn findings into a practical plan. Its most useful contribution is a clearer set of priorities, with the time and follow-up needed to act on them.
Cardiovascular preventionA heart CT can help answer an important question about prevention or chest symptoms—but different scans reveal different things. A calcium score measures hardened plaque, while CT angiography shows the arteries and their narrowing in more detail. Understanding that difference helps you and your clinician choose the information that can actually guide your care.
NAD & cellular energyNAD helps cells turn nutrients into usable energy, which makes it a compelling target for research into aging and disease. Scientists are testing whether giving it by infusion can improve health. An encouraging heart-failure study offers one clue; smaller studies explain what happens during a drip. Together, they show where the idea is promising and why benefits for everyday energy, memory and healthy aging still need direct testing.
Longevity medicinesNMN and NR offer two ways to influence NAD metabolism. What a person gains depends on the goal: trials have produced interesting findings for muscle insulin sensitivity and walking, alongside results with no improvement in memory or routine metabolic measures. Here is how the two supplements compare and how to read their different results.
Measuring agingA useful test helps with the next decision: clarifying a risk, explaining a symptom or following a change in fitness. Blood pressure, molecular clocks and imaging measure different things. This guide compares them by the question you want to answer and shows when a result can become a practical care plan.
HLC research & XPRIZEHealthy aging becomes tangible when it means walking more easily, maintaining strength and staying independent. Our eight-week Prague pilot brought coordinated care and repeat measurement together in ten older adults, with encouraging changes in mobility and blood-sugar regulation. Alongside this work, our collaboration with Klothea Bio explores a new biological approach through Klotho. Both are part of a wider effort to turn longevity science into more years of useful function.
Blood and plasma therapiesCould changing the proteins circulating in our blood influence aging? Plasma-exchange research is exploring that possibility. A small human study found encouraging changes in some biological-age measurements partway through treatment, raising new questions about how the procedure affects the body. To understand the finding, it helps to know what an aging clock measures, why the treatment combination matters, and what researchers still need to learn about lasting health benefits.
Blood & plasma researchPlasma is a busy part of the body: it carries proteins, immune signals and other substances between tissues. Changing what circulates in it can be a powerful medical tool, and researchers are now exploring applications in healthy aging. From lowering certain pollutants to studying plasma-derived signals, the field offers several different ideas. Understanding what each procedure removes or adds is the key to understanding its promise.
Klotho & translational researchKlotho is a protein our bodies already make, and it has become one of the most intriguing leads in aging research. Studies in older animals suggest that it can influence memory, physical function and, in some circumstances, lifespan. The next step is to understand how to use that biology safely in people. We explain what makes Klotho interesting, how the different treatment approaches work, and why Healthy Longevity Clinic is involved in this research.
Blood and plasma therapiesBlood carries much more than oxygen and nutrients. Its liquid component, plasma, contains signals that help tissues communicate—and some may influence how we age. E5 research explores whether selected components from young pigs’ plasma can support healthier aging. Small rat studies have reported encouraging changes in function, molecular age and lifespan. The challenge now is to understand what drives those effects and whether they can become a useful treatment for people.
Translational longevity researchA longer life means more when it includes more good years: walks, play, curiosity and companionship. Dogs may help us understand how to preserve those years. Research ranging from LeapYears supplements to gene therapy is exploring ways to support the aging brain and body, while larger trials ask whether treatments can help dogs live longer. The discoveries matter for our pets—and may also open new paths in human medicine.
Gut health & diagnostic testingA small stool sample can help answer very different questions: is there hidden blood, inflammation, an infection—or simply a distinctive community of microbes? Understanding that difference makes it easier to choose a useful test and make sense of a colorful microbiome report. The most valuable result is one that helps you decide what to do next.
Clinical trials & researchTaking part in a clinical trial can help move medicine forward and may offer access to a promising new approach. The first step is understanding what the study is trying to learn and what participation would mean for you. Three longevity-related examples show how to read a trial listing, recognize its limits and prepare useful questions about treatment, visits, costs and safety.
Midlife hormone assessmentHot flashes, disrupted sleep, changing periods or sexual difficulties can make midlife feel unfamiliar. You do not need to know whether hormones are responsible before asking for help. A good assessment starts with what has changed and what you want to improve, then uses the right combination of conversation, examination and selected tests.
Persistent fatigueFeeling persistently exhausted when your blood tests look normal can be frustrating. The results are useful, but they are only part of the picture. Sleep, medicines, iron stores and what happens after activity can all offer clues. A focused conversation can help identify treatable contributors and build a plan for daily life while the cause is being explored.
Biomarkers & health outcomesA better blood test can be welcome news. The next question is what it means for your life: more energy, preserved memory, fewer heart attacks or a lower chance of serious illness. Recent studies show why that connection deserves attention. They also show how researchers move from an encouraging biological signal to evidence that a treatment truly helps people.
Understanding the evidenceA headline about living longer can be exciting without telling you whether a discovery belongs in your own care. Five simple questions can bring a study into focus: who took part, what it was compared with, what improved, how long it lasted and who was involved. You do not need to be a statistician to start a better conversation about the evidence.
Exosomes & extracellular vesiclesCells communicate partly through tiny packages that carry biological cargo. Exosome research asks whether we can turn that communication system into useful treatments. Early human studies offer some encouraging skin findings, alongside disappointing results elsewhere. Understanding the promise starts with a simple point: the contents of the package, and where it is delivered, matter.
Muscle health & body compositionStaying strong means being able to carry your groceries, climb stairs and keep doing the things you enjoy. Your weight tells only part of that story. Body-composition measurements, strength tests and everyday movement together give a clearer picture of muscle health—and help shape a practical plan for preserving it.
Stem-cell evidence & regulationThe appeal of stem-cell treatment is easy to understand: help damaged tissue recover, reduce pain and restore movement. Florida’s rules have brought renewed attention to that possibility by allowing certain uses under state conditions. To make sense of an offer, it helps to connect three things—the exact cell product, the rules governing it and the health improvement its studies actually support.
Fitness & exercise testingYour watch can give you a convenient estimate of fitness. A laboratory VO₂ test goes further by measuring oxygen use while you exercise and showing how your heart, lungs and muscles respond as the effort rises. That fuller picture can help shape training or investigate an exercise limitation. Here is what happens during the test and how to make sense of the result.
Experimental treatment regulationMontana is testing a new approach to experimental medicine: licensed centers where certain investigational treatments can be considered under state rules. The framework reaches beyond the patient criteria of federal right to try and sets requirements for clinical review, consent and follow-up. Its promise depends on how those responsibilities work in practice—and on the evidence for each treatment.
Blood tests & preventionA few well-chosen blood tests can reveal opportunities to protect your heart, prevent diabetes and check how treatment is working. The useful selection depends on your history and what has already been measured. Here is how the common midlife tests fit together, which ones need a more personal discussion and what to do when a result is flagged.
Clinical trials & treatment accessWhen an approved treatment is not helping enough, news of an experimental option can offer hope—and a confusing set of choices. A clinical trial, expanded access and right to try are different ways an investigational treatment may reach a patient. Understanding their purpose, safeguards and practical limits makes the conversation with a clinician more useful.
Brain health & preventionA vaccine best known for preventing a painful rash has become an unexpected lead in dementia research. Several studies suggest that shingles vaccination may also help protect the brain. The possibility is exciting, but the results are not yet conclusive. Here is how a birthday rule opened this line of research—and what it means for vaccination decisions today.
Cardiovascular preventionImagine treating high cholesterol with a single infusion that helps the liver keep LDL levels lower for years. Gene editing is moving that possibility into human research. Early studies have produced substantial reductions in blood fats, opening a new chapter in prevention—while leaving the long-term benefits and risks to be established.
Cardiovascular preventionSome cardiovascular risk is inherited, and lipoprotein(a), or Lp(a), can reveal a part that routine cholesterol tests miss. Knowing your level can help shape prevention even while new treatments are being tested. The first major HORIZON result was disappointing: lowering Lp(a) with pelacarsen did not establish the hoped-for reduction in serious events. Here is what that finding means for the science—and what a high result can still help you do today.
Hormones and midlife healthHot flashes, night sweats and vaginal discomfort can make midlife unnecessarily difficult. Hormone therapy can offer meaningful relief, and revised US warnings are helping bring the conversation back to the individual woman. The choice depends on her symptoms, health history and the type of treatment. We explain what changed, why timing and route matter, and what research says about the wider hopes for heart, brain and long-term health.
Supplements and healthy agingA familiar molecule became a major longevity story when taurine helped mice live longer. The finding opened an appealing possibility: could something our bodies already make help preserve health with age? Later research has made the story more interesting—and more complicated. Blood taurine does not simply fall as everyone gets older, and human trials are now testing which benefits, if any, supplementation can deliver.
PeptidesInsulin and semaglutide have established benefits in defined conditions. BPC-157, TB-500 and MOTS-c have much earlier evidence for healing or physical performance. This guide compares the actual human findings, explains why similar peptide names can hide different treatments, and shows how Healthy Longevity Clinic weighs disease prevention, recovery and function against risk.
PeptidesThe seven-amino-acid fragment called TB-500 has no demonstrated healing benefit in people. Human eye and heart studies tested different preparations. One eye trial enrolled 18 people and missed its main goal; a later trial also missed it. The distinction matters: a promising result for one molecule cannot establish what another does.
PeptidesMK-677, CJC-1295, ipamorelin, sermorelin and capromorelin differ in their evidence for strength, mobility and cognition. In a 65-person trial, MK-677 increased fat-free mass without improving strength or function, while blood glucose rose. Other studies found narrower benefits. Healthy Longevity Clinic examines which results could support independence, and where hormonal changes leave the clinical question unanswered.
Removing damaged cells helped some mice, but worsened disease in other experiments. FOXO4-DRI’s 2017 results opened a research path, not a proven anti-aging treatment. Cleara is developing distinct candidates for cancer and reports preclinical progress. The central question is which cells can be removed without harming the tissue they live in.
PeptidesThe larger LL-37 leg-ulcer trial found no overall healing benefit: confirmed closure was about 25% with or without the peptide. Smaller studies and laboratory work remain interesting, but LL-37 also affects human cells. Maxwell Biosciences’ engineered peptoids take a different chemical approach; their reported milestones are progress toward testing, not proof of patient benefit.
PeptidesBPC-157 has not convincingly shown that it heals injuries in people. A September 2026 analysis found 279 reports of improvement among 1,039 users—but 685 had no recorded outcome. Small human studies offer clues, not a reliable benefit or safety estimate. A planned 120-person hamstring trial could provide a stronger test.
PeptidesMOTS-c can rise during exercise, but taking it has not been shown to reproduce exercise’s benefits. A 2021 study measured the peptide in ten young men who cycled; it did not treat them. A planned 120-person treatment trial could test whether MOTS-c improves the body’s response to insulin.
PeptidesThe often-cited study of 266 older people did not test Epitalon. It tested gland extracts, including Epithalamin. Epitalon itself has laboratory telomere findings and limited human reports, but no demonstrated healthy-aging or sleep benefit. The similar names hide the most important distinction.
PeptidesThymosin alpha-1 has a substantial human research record, but that record does not establish healthy-aging benefit. In the 2025 TESTS sepsis trial, 28-day mortality was 23.4% with treatment and 24.1% with placebo. Some vaccine studies found immune-marker changes. Whether generally healthy older adults get fewer serious infections remains unanswered.
PeptidesBPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon were evaluated for specific pharmacy-compounding uses at the July 23–24, 2026 FDA meeting. The meeting did not approve them as medicines. This guide explains the separate decisions on compounding, drug approval and GHK-Cu administration—and why US changes do not authorize a product in the EU or Czechia.
Peptides“Research use only” does not mean a product is suitable for treatment. In a small 2024 study, three products bought online as semaglutide contained 29%–39% more active drug than their labels stated; one also had elevated bacterial toxins. Those findings concern the tested products, but illustrate why identity, amount, contamination, and clinical benefit need separate answers.
Frontiers of longevityPartial reprogramming has reached human testing. ER-100’s sponsor announced first dosing in June 2026, in an eye-disease study planning 18 adults. The trial asks first about safety; whether it improves useful vision remains unanswered. Mouse experiments provide a scientific rationale, but the human evidence dated September 21, 2026 contains no reported outcomes showing restored sight or broader rejuvenation.
PeptidesBPC-157 is prohibited in and out of competition under the 2026 World Anti-Doping Agency (WADA) list. That matters for amateurs as well as professionals when their sport applies those rules. A prescription does not create an exemption, and the US Anti-Doping Agency (USADA) calls a BPC-157 exemption unlikely, not impossible. Start with your governing authority, the exact substance, and the medical reason for treatment.
Measuring agingBiological-age tests can disagree because they measure different features of aging and compare you with different reference groups. A repeat test can also change without showing a lasting health change. In a 2026 analysis of 18 DNA-based aging measures, many were more consistent when the same sample was measured again than when fresh samples were collected. That distinction matters when interpreting your own result.
Medicines and longevityRapamycin (sirolimus) has mixed human evidence for healthy aging. PEARL found no improvement in its main body-fat measure over 48 weeks, and RAPA-EX-01 found no added functional benefit alongside exercise. Everolimus improved selected vaccine responses, while a larger RTB101 trial missed its respiratory-illness endpoint. Healthy Longevity Clinic weighs these results by function, infection prevention and tolerability.
Medicines and longevityMetformin helps control type 2 diabetes and reduced new diabetes cases by 31% relative to placebo in the Diabetes Prevention Program. That is a meaningful healthspan benefit for people at high risk. This review distinguishes established prevention from newer frailty findings, exercise trade-offs and the proposed TAME trial, which aims to test broader prevention of age-related disease.
Measuring agingWhole-body MRI can discover an unsuspected cancer or another important abnormality. A review of ten studies involving 9,024 people without symptoms estimated roughly 16 confirmed cancers per 1,000 people screened. That is detection, not a count of lives saved. Scans can also trigger further tests for uncertain findings, and longer life from routine screening of well, average-risk adults has not been established.
Medicines and longevitySemaglutide has shown benefits beyond weight loss. In SELECT, serious cardiovascular events occurred in 6.5% of treated adults versus 8.0% with placebo; participants had cardiovascular disease and overweight or obesity, without diabetes. Kidney and symptom benefits in other defined groups add to the healthspan picture. Healthy Longevity Clinic examines who benefited, how much, and which risks affect the decision.
Medicines and longevityRetatrutide has produced substantial weight loss in clinical trials. In one phase 3 study, Lilly reported an average reduction of 28.7% versus 2.1% with placebo over 68 weeks in an analysis assuming continued treatment. Published research also shows improved glucose control in type 2 diabetes. These benefits warrant attention, but cardiovascular protection, long-term safety and an approval date remain unsettled.
Frontiers of longevityTRIIM, supported by Intervene Immune, reported improved thymus imaging in seven of nine men after a year of treatment, alongside selected immune and DNA-age changes. The study had no untreated control group. Healthy Longevity Clinic examines the promise of thymus regeneration for immune health and why the next decisive evidence should concern useful immune function, fewer serious infections and safety.
Medicines and longevityDasatinib–quercetin, fisetin and the experimental drugs UBX0101 and UBX1325 test whether removing senescent cells can improve bone, lung, joint or eye health. Results are mixed: several trials missed their main goals, while narrower biological and visual signals warrant follow-up. Healthy Longevity Clinic compares the prospects for fewer fractures, better mobility and preserved vision, together with treatment risks.
Measuring agingBrainKey and NeuroQuant turn brain MRI scans into measurements that can inform assessment of memory and thinking problems. They measure different features and require interpretation alongside symptoms and cognitive tests. Healthy Longevity Clinic explains brain volume, percentiles and “brain age,” showing which findings can support a care decision and why a low percentile alone is not a dementia diagnosis.
Frontiers of longevityER-100 reprogramming, telomerase mRNA, SIRT6, TRIIM thymus regeneration, senolytics, mitochondrial transplantation, cholesterol degradation, Klotho mRNA and plasma fractions target different aspects of age-related decline. This September 2026 overview compares all nine approaches, their human or preclinical evidence, and the next useful outcomes: preserved vision, stronger immunity, tissue recovery and fewer serious illnesses. Healthy Longevity Clinic explains which developments merit attention.
Frontiers of longevityTelomerase mRNA lengthened telomeres by up to about 900 DNA building blocks in cultured human cells in a 2015 experiment. Rejuvenation Technologies is developing this approach for impaired tissue maintenance, including fibrosis. Healthy Longevity Clinic examines the potential for tissue repair, the gap between cell results and patient outcomes, and why delivery and long-term safety are central to clinical progress.
Frontiers of longevityGenflow reports that its SIRT6 gene therapy met the main DNA-based age endpoint in 24 older beagles. The announcement provides no numerical effect size, so the extent and practical meaning of the result remain unclear. Healthy Longevity Clinic examines the findings alongside earlier mouse research and asks what complete safety, physical-function and survival data would add.
Measuring healthCHIP and CCUS describe blood-cell changes that can help specialists assess blood-cancer risk and follow-up needs; a mutation alone is not a cancer diagnosis. AgeCurve’s Cell Tree Rings studies a separate use of blood-cell relationships: estimating age. Healthy Longevity Clinic explains what each result means, how cardiovascular risk fits in, and its own contribution to the Cell Tree Rings research.
Measuring healthOccuity PM1 measures corneal thickness; its Indigo and SD1 programs explore glucose measurement and diabetes-risk screening. These uses differ from LumineticsCore, which has a defined US authorization for diabetic retinopathy screening. Healthy Longevity Clinic compares the evidence for each approach and explains when an eye measurement could guide follow-up, protect vision or support a more informed health decision.
Measuring healthSiPhox Health illustrates the growing interest in home blood testing. Studies of selected capillary tests show useful agreement with venous results, including after mailing, but sample quality and the exact assay matter. Healthy Longevity Clinic explains the difference between home collection and home analysis, which results can guide care, and when repeating a test is likely to add useful information.
Frontiers of longevitySENISCA is developing RNA-splicing approaches to change how senescent cells behave, with programs in lung fibrosis and skin health. Laboratory studies show that selected cell functions can recover, although DNA damage and other responses do not always improve together. Healthy Longevity Clinic compares this strategy with senolytics and asks whether it could preserve tissue function without unsafe cell growth.
Frontiers of longevitySemaglutide and tirzepatide can reduce lean tissue as well as fat. Exercise and adequate nutrition help make strength and independence central to weight-loss care. Bimagrumab has human body-composition results; MitoRx’s MTRX31 and Juvena’s JUV-161 explore further muscle-preserving approaches at earlier stages. Healthy Longevity Clinic compares what the findings mean for physical function, beyond a lower number on the scale.
Frontiers of longevityArtery plaque can shrink. Established cholesterol-lowering treatment reduces cardiovascular events and has produced modest plaque shrinkage in human imaging trials. Repair Biotechnologies is investigating a different approach: helping liver cells process excess cholesterol. Its mouse findings support further research, but do not establish how much human plaque would shrink, whether heart attacks would fall, or whether the treatment is safe in people.
Blood and plasma therapiesRepeated plasma donation lowered selected PFAS blood levels in a randomized trial of 285 Australian fire-service personnel. After a year, PFOS fell by an average of 2.9 ng/mL in the plasma group. That is a real measured effect. It does not establish permanent clearance from the whole body or better health, and the findings cannot be transferred to microplastics.
Frontiers of longevityMitochondrial transplantation has produced encouraging early heart-recovery findings. In one small comparison, 8 of 10 treated children came off heart-lung support for at least a week, versus 4 of 14 controls. Mitrix Bio is developing separate infusion and bioreactor programs. Healthy Longevity Clinic examines the prospects for recovery, physical capacity and independence, and the evidence each approach still needs.
Medicines and longevityMetformin, semaglutide and dapagliflozin reduce diabetes or serious heart and kidney events in defined patient groups. Evidence for rapamycin (sirolimus), the senolytic combination dasatinib–quercetin and the NAD precursor nicotinamide riboside (NR) remains early or mixed. This September 2026 overview also compares testosterone and menopausal hormone therapy. Healthy Longevity Clinic assesses their healthspan value through disease prevention, physical function and symptom relief.
Measuring healthGalleri received a favorable FDA advisory-panel vote on September 23, 2026. That is a meaningful step toward approval. For someone considering the blood test, the next question is what it adds to existing cancer screening. NHS-Galleri found encouraging detection signals but did not meet its primary combined stage III–IV endpoint; a reduction in cancer deaths remains unproven.